Ironwood Pharmaceuticals (IRWD) Price to Earnings (2010 - 2026)

Ironwood Pharmaceuticals has disclosed Price to Earnings across 17 years of filings, most recently posting 13.56 for Q2 2026.

• In Q2 2026, Price to Earnings rose 173.68% year-over-year to 13.56; the TTM figure through Jun 2026 stood at 3.15 (up 153.06% YoY), while the FY2025 annual figure was 4.77, down 30.89% from the prior year.
• Price to Earnings came in at 13.56 for Q2 2026 at Ironwood Pharmaceuticals, down from 14.17 in the prior quarter.
• In the past five years, Price to Earnings ranged from a high of 180.82 in Q3 2024 to a low of 1211.04 in Q2 2024.
• Average Price to Earnings over 5 years is 54.14, with a median of 13.87 recorded in 2026.
• Year-over-year, Price to Earnings jumped 789.36% in 2022 and plunged 79379.09% in 2024.
• Over 5 years, Price to Earnings stood at 39.05 in 2022, then decreased by 15.69% to 32.93 in 2023, then plunged by 79.31% to 6.81 in 2024, then slipped by 9.25% to 6.18 in 2025, then jumped by 119.37% to 13.56 in 2026.
• Per Business Quant data, the three most recent Price to Earnings figures were 13.56 in Q2 2026, 14.17 in Q1 2026, and 6.18 in Q4 2025.